Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does Ocular's Latest CRL Mean A Minor Delay For Dextenza, Or A New NDA?

Executive Summary

The biotech sought a three-month action date extension with new manufacturing process data submitted to FDA just one day before the complete response letter.

You may also be interested in...



Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade

Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.

Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

The latest drug development news and highlights from our US FDA Performance Tracker.

Ocular Therapeutix Gets Lead Product Back On Track

The long-acting eye insert Dextenza has been accepted for review by the US FDA, a piece of good news for Ocular Therapeutix that had previously received a complete response letter on manufacturing issues and a mixed bag of late-stage clinical trial results.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel